News

With November comes National Alzheimer’s Awareness Month, an annual effort to recognize the impact of the neurodegenerative disease in the U.S., where about 6.2 million people are affected by it. Each November, the Alzheimer’s Foundation of America (AFA) offers supporters a range of different ways to raise awareness…

Weekly injections of an investigational formulation of the Alzheimer’s disease therapy Leqembi (lecanemab) worked better than the approved treatment in removing harmful amyloid beta plaques from patients’ brains over six months in a Phase 3 trial. In fact, the subcutaneous or under-the-skin formulation cleared 14% more plaques in…

Medicare, the U.S. health insurance program for people ages 65 and older, will now provide additional coverage for an imaging test, called an amyloid PET scan, that can be used to help diagnose and monitor Alzheimer’s disease. The decision by the Centers for Medicare and Medicaid Services (CMS)…

An ongoing Phase 2/3 clinical trial testing Annovis Bio’s treatment candidate buntanetap in people with Alzheimer’s disease is expected to be fully enrolled next month, with trial data anticipated in March 2024, according to a company update. These estimations come after a recent six-week interim analysis of 107…

A research team led by scientists at the Massachusetts Institute of Technology (MIT) has completed the most sweeping analysis yet of how genetic activity in brain cells is dysregulated in Alzheimer’s disease. “What we set out to do was blend together our computational and our biological expertise and take…

Six months of treatment with bryostatin slowed cognitive decline in adults with moderately severe Alzheimer’s disease, according to new data from a Phase 2 clinical trial. These bryostatin-associated cognitive benefits over a placebo were maintained even four months after stopping treatment, the researchers noted — highlighting the long-term effects…

Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant. These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose…

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data analysis of a Phase 2b/3 clinical trial. The cognitive benefits were accompanied by a slower rate of brain shrinkage, a marker…

Among people with a genetic form of Alzheimer’s disease, those with more formal education tend to be older at disease onset, a new study suggests. Data indicate that the protective effects of education are particularly pronounced among patients with the highest genetic risk of Alzheimer’s, which suggests that “programs to…

As part of this month’s observance of World Alzheimer’s Month, supporters intend to raise awareness about Alzheimer’s disease and other types of dementia by pointing out the risk factors associated with the disorders. The Alzheimer’s Disease International (ADI) organizes the event, working with and supporting patient groups in…